Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4

被引:509
作者
Triballeau, N [1 ]
Acher, F
Brabet, I
Pin, JP
Bertrand, HO
机构
[1] Accelrys SARL, F-91893 Orsay, France
[2] Univ Paris 05, UMR8601 CNRS, Chim & Biochim Pharmacol & Toxicol Lab, F-75270 Paris, France
[3] CCIPE, Lab Genom Fonctionnelle, Dept Mol Pharmacol, F-34094 Montpellier, France
关键词
D O I
10.1021/jm049092j
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The "receiver operating characteristic" (ROC) curve method is a well-recognized metric used as an objective way to evaluate the ability of a given test to discriminate between two populations. This facilitates decision-making in a plethora of fields in which a wrong judgment may have serious consequences including clinical diagnosis, public safety, travel security, and economic strategies. When virtual screening is used to speed-up the drug discovery process in pharmaceutical research, taking the right decision upon selecting or discarding a molecule prior to in vitro evaluation is of paramount importance. Characterizing both the ability of a virtual screening workflow to select active molecules and the ability to discard inactive ones, the ROC curve approach is well suited for this critical decision gate. As a case study, the first virtual screening workflow focused on metabotropic glutamate receptor subtype 4 (mGlu4R) agonists is reported here. Six compounds out of 38 selected and tested in vitro were shown to have agonist activity on this target of therapeutic interest.
引用
收藏
页码:2534 / 2547
页数:14
相关论文
共 72 条
[1]   Integration of virtual and high-throughput screening [J].
Bajorath, F .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (11) :882-894
[2]   Evaluating the predictive accuracy of six risk assessment instruments for adult sex offenders [J].
Barbaree, HE ;
Seto, MC ;
Langton, CM ;
Peacock, EJ .
CRIMINAL JUSTICE AND BEHAVIOR, 2001, 28 (04) :490-521
[3]   Glutamate and anxiety [J].
Bergink, V ;
van Megen, HJGM ;
Westenberg, HGM .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 (03) :175-183
[4]   Common and selective molecular determinants involved in metabotopic glutamate receptor agonist activity [J].
Bertrand, HO ;
Bessis, AS ;
Pin, JP ;
Acher, FC .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (15) :3171-3183
[5]   Closure of the Venus flytrap module of mGlu8 receptor and the activation process:: Insights from mutations converting antagonists into agonists [J].
Bessis, AS ;
Rondard, P ;
Gaven, F ;
Brabet, I ;
Triballeau, N ;
Prézeau, L ;
Acher, F ;
Pin, JP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (17) :11097-11102
[6]   Peripheral group I metabotropic glutamate receptors modulate nociception in mice [J].
Bhave, G ;
Karim, F ;
Carlton, SM ;
Gereau, RW .
NATURE NEUROSCIENCE, 2001, 4 (04) :417-423
[7]  
BLOW D, 2002, OUTLINE CRYSTALLOGRA, P236
[10]   Informative library design as an efficient strategy to identify and optimize leads: Application to cyclin-dependent kinase 2 antagonists [J].
Bradley, EK ;
Miller, JL ;
Saiah, E ;
Grootenhuis, PDJ .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (20) :4360-4364